Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sinomenine is a bioactive alkaloid extracted from the Chinese medicinal plant Sinomenium acutum. It exhibits significant pharmacological effects, including anti-inflammatory, analgesic (pain-relieving), immunosuppressive, antihypertensive, and anti-arrhythmic activities[2][5][8]. Its primary mechanism involves inhibition of cyclooxygenase-2 (COX-2) expression and modulation of inflammatory cytokines such as TNF-α and IL-1β[5][6]. Sinomenine also potently releases histamine by degranulating tissue mast cells, leading to vasodilation and increased vascular permeability in skin and joint capsules[3]. Clinically, it is used for the treatment of rheumatoid arthritis (RA), osteoarthritis, neuralgia, and gouty arthritis in China under various formulations including tablets (e.g., Zhengqing Fengtongning), injections, sustained-release agents, and transdermal preparations[1][2][4][6]. It has demonstrated efficacy in reducing joint pain/swelling/stiffness in RA patients while lowering inflammatory markers such as CRP and ESR. Side effects are generally mild but may include fatigue or allergic reactions at higher doses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sinomenine.